Disuf-B

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Disuf-B

Disuf-B is a prescription combination product used topically, designed to address the dual components of inflammation and bacterial infection in specific skin conditions.

Quick Facts
Active Ingredients Betamethasone Dipropionate, Fusidic Acid
Form Topical Cream or Ointment
Pharmacological Class Corticosteroid-Antibiotic Combination
General Purpose To manage inflammatory skin reactions complicated by bacterial presence
Origin Synthetic (Betamethasone) and Derived (Fusidic Acid)

The Pharmacological Identity of Disuf-B

Disuf-B is fundamentally defined as a potent Topical Corticosteroid-Antibiotic preparation containing two active pharmaceutical entities: the synthetic glucocorticoid Betamethasone Dipropionate and the antibiotic Fusidic Acid. The formulation's primary differentiation lies in the pairing of a high-potency steroid with an anti-infective known for its ability to penetrate skin tissue. Betamethasone is clinically recognized for its significant anti-inflammatory power, providing rapid resolution of severe erythema and swelling.

Composition and Pharmaceutical Form

The dual composition ensures that Betamethasone Dipropionate provides powerful anti-inflammatory effects while Fusidic Acid provides specific antibacterial action. Fusidic Acid possesses targeted activity against bacteria commonly associated with secondary skin infections, which works by stopping bacteria from making necessary proteins. Disuf-B is typically provided as a topical cream or ointment, utilizing a semi-solid dosage form for precise cutaneous administration to the affected site.

General Therapeutic Purpose

The overall purpose of Disuf-B is to provide efficient symptom relief and localized bacterial control. The integrated composition is designed to quickly calm the inflammatory process, significantly reducing distressing symptoms such as intense itching, swelling, and redness. A typical scenario for its general use is the management of an already inflamed skin lesion that shows evidence of bacterial involvement.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Disuf-B?

Possible Side Effects and Safety Information

The safety profile for this topical corticosteroid-antibiotic combination is established by regulatory bodies, classifying potential effects primarily by frequency and the organ system involved. Reactions are generally organized into the Skin and subcutaneous tissue disorders and potential Endocrine disorders resulting from systemic exposure.

Adverse reactions classified as Uncommon (affecting up to 1 in 100 people) include pruritus (itching), skin burning sensation, and contact dermatitis. Reactions such as rash and erythema (redness) are documented as Rare.

Of greater regulatory significance are the systemic safety concerns related to the potent corticosteroid component. The potential for HPA axis suppression (a decrease in natural hormone production) and features of Cushing's syndrome are documented as serious adverse reactions, particularly when the medication is used for prolonged periods, over large body surface areas, or under occlusive dressings. These systemic risks are heightened in the pediatric population due to their increased surface area to body mass ratio.

Regulatory documents explicitly state that the product should not be used in specific skin conditions, such as Rosacea or Perioral dermatitis, and caution is advised regarding use near the eyes due to the risk of visual disturbances. The combination product's use is officially limited in duration to minimize the risk of both systemic side effects and the potential development of antibiotic resistance.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Disuf-B is primarily associated with the potential for systemic absorption of the Betamethasone Dipropionate component. This risk increases with prolonged, widespread, or excessive topical application, particularly when used under occlusive dressings.

Documented Manifestations and Serious Outcomes

Documented signs of systemic overdose include reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's syndrome. Other clinical findings listed in regulatory documents are hyperglycemia and adrenocortical insufficiency. Serious outcomes may involve profound steroid withdrawal signs upon abrupt cessation of excessive use.

Pediatric Risk and Emergency Actions

Pediatric patients demonstrate greater susceptibility to systemic effects, which may present as growth retardation or signs of intracranial hypertension. The Fusidic Acid component is considered unlikely to cause systemic harm from a single accidental oral dose.

In the event of a suspected overdose, regulatory guidance advises to contact your regional Poison Control Centre. Immediate medical attention is required for persistent or severe signs of hypercortisolism or HPA axis suppression. Management is typically symptomatic and supportive, aiming for the gradual withdrawal of the product or substitution with a less potent corticosteroid, as no specific antidote is known.

Therapeutic Uses of Disuf-B

What Disuf-B Treats: Main Uses and Benefits

Disuf-B is a medication focused on providing short-term, supportive relief across symptomatic domains where additional symptomatic support is needed. It is generally used across domains where symptoms related to inflammatory or irritative states become more noticeable. This medication is commonly applied in clinical settings marked by temporary physiological imbalance.


Easing Heightened Symptom Burden

This medicine is applied across conditions characterized by periods of heightened symptoms where supportive relief is needed. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. It is commonly used across conditions presenting with acute episodes where symptoms related to inflammatory or irritative states are significant.

Disuf-B is relevant for managing symptom clusters that may become intense or disruptive, such as localized discomfort and irritation. It is used in clinical scenarios where the patient experiences heightened discomfort, and this helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Supports Management of Localized Discomfort (This medicine may assist with easing the overall symptom load during episodes of heightened discomfort.)

Eligibility and Restrictions for Use

Who Can and Cannot Use Disuf-B?

Eligibility for Disuf-B (Betamethasone Dipropionate/Fusidic Acid) is strictly defined by regulatory documents, particularly concerning the potent corticosteroid component.

Contraindications and Restrictions

The medicine is contraindicated and must not be used in patients with known hypersensitivity to its active ingredients or in infants under one year of age with infected dermatitis. Due to the steroid content, it is also prohibited in patients with rosacea, perioral dermatitis, systemic fungal infections, or untreated primary infections caused by viruses (e.g., cold sores) or tuberculosis-related skin conditions.

Population Eligibility Status Specific Restriction
Infants (< 1 year) Contraindicated Use is prohibited due to risk of systemic absorption.
Children (ge 1 year) Allowed with Caution Increased risk of HPA axis suppression requires careful monitoring.
Pregnant Women Not Recommended Should not be used unless clearly necessary; animal studies show potential fetal risk.
Breastfeeding Women Allowed Use is permitted, but must not be applied directly to the breast.

Use is not restricted by regulatory bodies for patients with renal or hepatic impairment due to the drug's minimal systemic absorption. Patients predisposed to glaucoma or cataracts must use the product cautiously, especially near the eyes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the topical combination product Disuf-B (Betamethasone Dipropionate / Fusidic Acid) is primarily defined by its route of administration. Official regulatory documents state that interactions with systemically administered medicinal products are considered minimal.

This classification is due to the negligible systemic absorption of both active components when the product is used as directed. Accordingly, regulatory labels confirm that no formal interaction studies have been performed for the topical formulation.

Official Constraints and Limitations

Interaction Type Regulatory Status (Documented)
Contraindicated Combinations None explicitly prohibited due to drug-drug interaction risk.
Timing Requirements No mandatory timing separation rules are documented.
Food/Alcohol/Supplements No specific interactions are documented.

The overall interaction structure is characterized by a lack of specific, documented interactions for standard use. However, a caution exists regarding the potential for increased systemic exposure. The theoretical potential for systemic interaction is heightened in certain populations or conditions, specifically in pediatric patients, and with application to large areas, use under occlusion, or during prolonged treatment periods. Under these circumstances, increased absorption of the corticosteroid component may elevate the theoretical potential for systemic effects.

Mechanism of Action

How Disuf-B Works

Disuf-B employs a dual mechanism of action to influence distinct biological processes. This combination engages mechanisms that regulate dysregulated pathways and simultaneously suppresses sequences involved in microbial function.


Antibacterial Protein Synthesis Inhibition

This domain involves the fusidic acid component, which exerts an antimicrobial action against susceptible Gram-positive bacteria. The molecule interferes with protein synthesis by binding to the bacterial ribosome and preventing the release of elongation factor G (EF-G). This interaction blocks the ribosomal translocation step, thereby modifying the bacterial growth pathway and resulting in the physiological consequence of inhibiting bacterial replication.


Glucocorticoid Receptor-Mediated Suppression

The second component, a structural analogue of cortisol, acts within a domain involving receptor-mediated signaling. It binds to intracellular glucocorticoid receptors, and the resulting complex translocates to the nucleus to regulate gene expression. This nuclear action suppresses the synthesis of inflammatory mediators (e.g., prostaglandins and leukotrienes) and reduces immune cell signaling. This cascade supports a more regulated state within the targeted pathways, leading to the physiological effect of modulating excessive pathway activity.

Dosage and Administration Information

Official Administration Guidelines

Disuf-B is intended for cutaneous administration only, utilizing its semi-solid dosage form as a topical cream or ointment. The product contains the fixed-dose combination of Fusidic Acid 20 mg/g and Betamethasone 1 mg/g, which defines the strength for all administration.


Standard Dosing and Schedule

Route of administration: Topical application to the skin.

Dosing schedule: Application of a small quantity, or thin film, of the product to the affected area. Treatment should be discontinued once a satisfactory response is observed.

Frequency and timing: Application is scheduled twice daily, typically once in the morning and once in the evening.

Course duration: The duration of a single continuous treatment course must not exceed 14 days (two weeks). This time constraint is a mandatory usage instruction governing the limit of exposure.


Procedural Guidelines and Restrictions

The administration protocol requires that the product be gently rubbed into the skin. Patients are instructed to wash their hands before and after each application, except when the hands are the area being treated. The product must avoid contact with the eyes during application. For pediatric patients, the same maximum treatment duration of 14 days applies, and the product must be used with care due to increased systemic absorption susceptibility. For more resistant lesions, the therapeutic effect may be achieved using occlusion with polythene film, though this is not the standard application method.

Connection to the official use protocol: The established instructions define Disuf-B as a short-term, fixed-dose topical medication intended for strictly localized application, with a mandatory 14-day limit. This protocol defines the precise administration method (twice daily, thin film, cutaneous use) and required procedural steps, ensuring standardized and time-limited administration.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies

The evidence base for the Disuf-B combination product is rooted in formal clinical evaluations, primarily short-term, randomized controlled trials (RCTs). This section summarizes the structure of the available evidence as reported in regulatory documents and peer-reviewed scientific literature. The research was conducted to observe patterns related to conditions characterized by inflammatory and irritative states that also show evidence of bacterial involvement.


Evidence for Use in Eczema with Bacterial Presence

Research focusing on Disuf-B was largely applied in studies examining the short-term symptom patterns related to inflammatory skin conditions associated with bacterial presence. This clinical scenario involves an inflammatory skin condition where bacteria are present in the affected area.

The main body of evidence consists of short-term RCTs, where the medicine was studied for how symptoms change over time when compared to similar preparations or an inactive cream base. These studies explored how combining the two ingredients was observed in studies evaluating the overall disease state and the microbiological environment. The study outcomes examined included changes related to physical discomfort and outcomes linked to inflammatory or irritative states.

Primary Outcomes Measured in Pivotal Trials

Clinical trials that formed the basis of regulatory summaries specifically evaluated the treatment over defined time intervals. These trials used recognized methods to capture phases of heightened symptom activity. Researchers assessed overall change in the skin condition using investigator scales, which are relevant in evidence describing how symptoms are measured. Research provides insight into the short-term changes observed in the measurements of inflammatory signs and bacterial presence.


Examining Long-Term Studies and Follow-up Data

The research exploring Disuf-B focuses predominantly on short-term treatment periods, typically up to two weeks of continuous use. Follow-up durations were limited in the pivotal regulatory trials. Existing studies provide context but not individual predictions about the results of using the medicine beyond the studied period. As a result, long-term effects are not fully established.

Key Studies & References

  1. Safety and Efficacy of Fusidic Acid with Betamethasone Combination Cream for Pediatric Atopic Dermatitis with Secondary Infection
  2. Topical Corticosteroids - Clinical Pharmacology and Pediatric Safety Concerns

Frequently Asked Questions (FAQ)

Common questions about Disuf-B (FAQ)


Q: Does Disuf-B make you feel tired or sleepy?

A: Unusual tiredness or somnolence is not listed among the common side effects in the official product information for Disuf-B. However, in rare instances of high exposure due to prolonged or extensive use, signs of adrenal suppression may occur. These rare signs can potentially include symptoms described as tiredness, anxiety, or depression.


Q: How long does it typically take before Disuf-B starts working?

A: Studies and patient information indicate that improvement in the treated skin condition is typically noticed after a few days of using the cream. Regulatory instructions define a specific course duration, and the medicine should be used only for the time period prescribed by a healthcare provider.


Q: Do studies suggest Disuf-B is a long-term treatment?

A: No, regulatory guidance and clinical research clearly indicate that Disuf-B is intended only for short-term use. To limit the risk of systemic corticosteroid effects and the potential development of antibiotic resistance, regulatory guidance restricts the continuous use of the medicine to a maximum of 14 days.


Q: Will taking Disuf-B interfere with my birth control pills?

A: The official product information states that interactions with medicines taken by mouth, such as birth control pills, are considered minimal. This is due to the product’s topical application and the negligible amount of medicine that is absorbed into the bloodstream when used as directed.


Q: Can people with high blood pressure use Disuf-B?

A: Regulatory documents do not list high blood pressure as a specific contraindication or restriction for using Disuf-B. Warnings and precautions are primarily focused on specific skin infections, use in infants, and certain conditions like diabetes, glaucoma, or cataracts.


Q: Does Disuf-B interact with antidepressants?

A: The interaction profile for this topical product confirms that interactions with systemically administered medicines, including drugs like antidepressants, are considered minimal. This is because the drug is applied to the skin, resulting in negligible absorption into the body's main systems.


Q: How long does Disuf-B stay in my system after I stop taking it?

A: Formal data defining the exact pharmacokinetics—or how long the drug remains in the body—for the topical cream is not available. However, official information states that systemic absorption of the active ingredients is considered negligible when the medicine is used according to instructions.


Q: Can I take Disuf-B if I drink coffee every day?

A: Regulatory sources do not document any specific interactions regarding food, drink, or daily coffee consumption. Since Disuf-B is a topical product with minimal absorption, major interactions with dietary habits are not anticipated.


Q: Is Disuf-B known to cause weight changes?

A: Weight changes are not listed as a common side effect of Disuf-B. However, systemic side effects like Cushing's syndrome—a rare condition linked to excessive or prolonged steroid use—can be associated with changes in body composition, which may include weight gain.


Q: Can Disuf-B interact with herbal supplements?

A: While formal interaction studies with herbal remedies and supplements are typically not performed for topical products, official guidance recommends that a healthcare provider be aware of all products being used. This practice is consistent with general drug safety advice.


Q: If I am pregnant, is Disuf-B an option for me?

A: Regulatory information advises that Disuf-B should not be used during pregnancy unless use is considered clearly necessary. This caution is due to limited human data and animal study findings related to the corticosteroid component showing potential for fetal harm.


Q: Are there any known risks of taking Disuf-B while breastfeeding?

A: Use of Disuf-B is generally permitted while breastfeeding. This is because systemic exposure to the infant is anticipated to be negligible. However, for safety, the product must not be applied directly to the breast area.


Q: Is Disuf-B an opioid or habit-forming drug?

A: Disuf-B is a topical corticosteroid-antibiotic combination and is not classified as a controlled substance or an opioid in official drug databases. It is not considered habit-forming.


Q: Can people with diabetes use Disuf-B?

A: Caution is advised for patients with diabetes using Disuf-B. The corticosteroid component has the potential to cause elevated blood sugar (hyperglycemia) or sugar in the urine (glucosuria) in some individuals, and monitoring may be necessary.


Q: Does Disuf-B contain lactose or gluten?

A: The official list of documented excipients (inactive ingredients) for the topical cream formulation does not include lactose or gluten. Common excipients include substances like cetostearyl alcohol and liquid paraffin.


Q: Are there any known interactions between Disuf-B and grapefruit?

A: Official regulatory sources do not document any specific interactions between Disuf-B and grapefruit or other foods. This is consistent with its topical route of administration and minimal systemic absorption.


Q: Is Disuf-B known to cause hair loss?

A: Hair loss is not listed as a known or common side effect of Disuf-B. Conversely, prolonged use of potent topical corticosteroids has been rarely associated with the opposite effect: increased growth of body hair (hypertrichosis).


Q: Will Disuf-B still work if I miss a dose occasionally?

A: According to the patient information leaflet, if a dose is forgotten, the product should be applied as soon as the patient remembers. The regular twice-daily dosing schedule should then be immediately resumed.


Q: Can older adults (seniors) safely use Disuf-B?

A: Regulatory documents do not establish specific dosage adjustments or restrictions based solely on advanced age. The precautions and guidance for use in the geriatric population are generally the same as for other adult patients.


Q: Does Disuf-B interact with common pain relievers like ibuprofen?

A: Interactions with oral pain relievers or other systemically acting medicines, such as ibuprofen, are considered minimal. This is due to the topical administration of Disuf-B and the very low amount of medicine absorbed into the body.


Q: What happens if Disuf-B is taken with certain antifungals or antibiotics?

A: The topical product has minimal systemic interactions. However, official guidance recommends that a healthcare provider be aware of all concurrent medicines, including other anti-infectives, as the corticosteroid component may potentially mask or suppress the signs of an existing fungal or other underlying infection.


Q: Is Disuf-B linked to any changes in mood or anxiety?

A: Changes in mood, such as depression or anxiety, are not common side effects. They are cited as potential, rare signs of adrenal suppression, a serious systemic effect that may occur with inappropriate or excessive use of the corticosteroid component.


Q: Are there any known drug-disease interactions for Disuf-B (besides its main purpose)?

A: Yes, there are contraindications and precautions related to other diseases. The medicine must not be used on skin with rosacea, perioral dermatitis, or untreated viral or fungal infections. Caution is also advised for patients with certain conditions like diabetes.


Q: What are the current research topics being studied for Disuf-B?

A: Recent research and clinical trials have focused on the efficacy and safety of newer formulations of the combination product, such as a lipid cream, compared to its individual components. These studies continue to focus on conditions like infected atopic dermatitis.


Q: Is the long-term safety profile of Disuf-B known?

A: The long-term safety profile is not fully established. Clinical evidence and regulatory guidance strictly restrict continuous treatment to short periods, typically no more than 14 days, which limits the ability to study effects beyond this duration.

How should Disuf-B be stored and disposed of?

Storage and Handling

Disuf-B must be stored in its original container at a controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). To maintain the product's stability and protect it from moisture, the container must be kept tightly closed when not in use.

It is a mandatory safety requirement to keep this medicine and all other drugs out of the sight and reach of children and pets at all times to prevent accidental ingestion.

Disposal of Unused Medicine

Official regulatory guidelines for Disuf-B emphasize the use of drug take-back programs, such as those run by pharmacies or law enforcement, for the disposal of unused or expired medicine. This is the preferred method.

If a take-back option is not readily available, the medicine should be disposed of in household trash. To prepare it, the product must be mixed with an undesirable substance, such as used coffee grounds or cat litter, sealed in a container (like a plastic bag), and then discarded. Do not flush Disuf-B down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Disuf-B found in:

A-Z Index: